PD-L1 and IFN-γ Modulate Non-Small Cell Lung Cancer (NSCLC) Cell Plasticity Associated to Immune Checkpoint Inhibitor (ICI)-mediated Hyperprogressive Disease (HPD)

Background: Non-Small Cell Lung Cancer (NSCLC) is the leading cause of cancer death worldwide. Although immune checkpoint inhibitors (ICIs) have shown remarkable clinical efficacy, they can also induce a paradoxical cancer acceleration, known as hyperprogressive disease (HPD), whose causative mechanisms are still unclear.

Methods: This study investigated the mechanisms of ICI resistance in an HPD-NSCLC model. Two primary cell cultures were established from samples of a NSCLC patient, before ICI initiation ("baseline", NSCLC-B) and during HPD ("hyperprogression", NSCLC-H). The cell lines were phenotypically and molecularly characterized through immunofluorescence, Western Blotting and RNA-Seq analysis. To assess cell plasticity and aggressiveness, cellular growth patterns were evaluated both in vitro and in vivo through 2D and 3D cell growth assays and patient-derived xenografts establishment. In vitro investigations, including the evaluation of cell sensitivity to interferon-gamma (IFN-γ) and cell response to PD-L1 modulation, were conducted to explore the influence of these factors on cell plasticity regulation.

Results: NSCLC-H exhibited increased expression of specific CD44 isoforms and a more aggressive phenotype, including organoid formation ability, compared to NSCLC-B. Plastic changes in NSCLC-H were well described by a deep transcriptome shift, that also affected IFN-γ-related genes, including PD-L1. IFN-γ-mediated cell growth inhibition was compromised in both 2D-cultured NSCLC-B and NSCLC-H cells. Further, the cytokine induced a partial activation of both type I and type II IFN-pathway mediators, together with a striking increase in NSCLC-B growth in 3D cell culture systems. Finally, low IFN-γ doses and PD-L1 modulation both promoted plastic changes in NSCLC-B, increasing CD44 expression and its ability to produce spheres.

Conclusions: Our findings identified plasticity as a relevant hallmark of ICI-mediated HPD by demonstrating that ICIs can modulate the IFN-γ and PD-L1 pathways, driving tumor cell plasticity and fueling HPD development.

References

Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A . IFN-γ and CD38 in Hyperprogressive Cancer Development. Cancers (Basel). 2021; 13(2). PMC: 7830527. DOI: 10.3390/cancers13020309. View

Li G, Choi J, Kryczek I, Sun Y, Liao P, Li S . Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 2023; 41(2):304-322.e7. PMC: 10286807. DOI: 10.1016/j.ccell.2022.12.008. View

Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R . Novel patterns of response under immunotherapy. Ann Oncol. 2019; 30(3):385-396. DOI: 10.1093/annonc/mdz003. View

Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P . Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics. 2022; 12(7):3150-3177. PMC: 9065180. DOI: 10.7150/thno.67409. View

Barrat F, Crow M, Ivashkiv L . Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019; 20(12):1574-1583. PMC: 7024546. DOI: 10.1038/s41590-019-0466-2. View

Ivashkiv L . IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018; 18(9):545-558. PMC: 6340644. DOI: 10.1038/s41577-018-0029-z. View

Zhang C, Wang H, Wang X, Zhao C, Wang H . CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma. Cancer Cell Int. 2020; 20(1):583. PMC: 7720536. DOI: 10.1186/s12935-020-01671-4. View

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G . Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2018; 25(3):989-999. DOI: 10.1158/1078-0432.CCR-18-1390. View

Hudson K, Cross N, Jordan-Mahy N, Leyland R . The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Front Immunol. 2020; 11:568931. PMC: 7609400. DOI: 10.3389/fimmu.2020.568931. View

10.

Beziaud L, Young C, Madurga Alonso A, Norkin M, Minafra A, Huelsken J . IFNγ-induced stem-like state of cancer cells as a driver of metastatic progression following immunotherapy. Cell Stem Cell. 2023; 30(6):818-831.e6. DOI: 10.1016/j.stem.2023.05.007. View

11.

Grant M, Herbst R, Goldberg S . Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol. 2021; 18(10):625-644. DOI: 10.1038/s41571-021-00520-1. View

12.

Kalbasi A, Ribas A . Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2019; 20(1):25-39. PMC: 8499690. DOI: 10.1038/s41577-019-0218-4. View

13.

Ruzzi F, Angelicola S, Landuzzi L, Nironi E, Semprini M, Scalambra L . ADK-VR2, a cell line derived from a treatment-naïve patient with fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC. Transl Lung Cancer Res. 2022; 11(11):2216-2229. PMC: 9742620. DOI: 10.21037/tlcr-22-163. View

14.

Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L . ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell. 2020; 37(3):324-339.e8. DOI: 10.1016/j.ccell.2020.02.006. View

15.

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

16.

Mansour F, Al-Mazrou A, Al-Mohanna F, Al-Alwan M, Ghebeh H . PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis. Oncoimmunology. 2020; 9(1):1729299. PMC: 7153827. DOI: 10.1080/2162402X.2020.1729299. View

17.

Qi Y, Huang Y, Wang H, Zhang Y, Bao Y, Sun L . Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling. BMC Bioinformatics. 2013; 14:41. PMC: 3599299. DOI: 10.1186/1471-2105-14-41. View

18.

Alkaabi D, Arafat K, Sulaiman S, Al-Azawi A, Attoub S . PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression. Int J Mol Sci. 2023; 24(7). PMC: 10094894. DOI: 10.3390/ijms24076420. View

19.

Brabletz S, Schuhwerk H, Brabletz T, Stemmler M . Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021; 40(18):e108647. PMC: 8441439. DOI: 10.15252/embj.2021108647. View

20.

Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y . IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer. 2020; 8(1). PMC: 7319788. DOI: 10.1136/jitc-2019-000285. View